All In Biotech

NDA 014399 · Validus Pharms

Norpramin

Desipramine Hydrochloride · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Jun 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1964

Nov 20, 1964

Approved uses

2

Original approval plus efficacy supplements

Registered trials

39

6 Phase 3, 0 recruiting

FAERS reports

279

185 serious, 27 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studiesof major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely...

What it is approved for

From the label in effect Jul 3, 2025.

INDICATIONS AND USAGE NORPRAMIN is indicated for the treatment of depression.

Mechanism: Mechanism of Action Available evidence suggests that many depressions have a biochemical basis in the form of a relative deficiency of neurotransmitters such as norepinephrine and serotonin. Norepinephrine deficiency may be associated with relatively low urinary 3-methoxy-4-hydroxyphenyl glycol (MHPG) levels, while serotonin deficiencies may be associated with low spinal fluid levels of 5-hydroxyindoleacetic acid. While the precise mechanism of action of the tricyclic antidepressants is unknown, a leading theory suggests that they restore normal levels of neurotransmitters by blocking the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 10MG · TABLET, ORAL · Discontinued · TE AB
  • NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 100MG · TABLET, ORAL · Discontinued · TE AB
  • NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 50MG · TABLET, ORAL · Discontinued · TE AB
  • NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 25MG · TABLET, ORAL · Discontinued · TE AB
  • NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 150MG · TABLET, ORAL · Discontinued · TE AB
  • NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 75MG · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Desipramine" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective29
  • fatigue22
  • drug hypersensitivity17
  • nausea17
  • headache16
  • dyspnoea15
  • toxicity to various agents15
  • off label use14
  • confusional state13
  • dizziness12
  • vomiting12
  • depression11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200511
20069
20072
20085
20098
201012
201118
201216
20136
201411
201515
201617
201722
201816
201915
202012
20216
20228
202310
202415
202520
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 517 on PubMed

Sponsor: Validus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.